Skip to content

Hutchmed (China)

US · HCM #2639 by market cap Listed 2016
13.22 -0.23 -1.71%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:10

Recent news

  • Rating change
    Hutchmed (00013.HK): Positive Phase III Data for Savolitinib; Expansion of Indications Domestically and Internationally Expected to Unlock Growth Potential
    Guangfa Securities · 2026/10/29
  • HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
    GlobeNewswire · 2026/11/5
  • Rating change
    Hutchmed (0013.HK) Savolitinib: Two Phase III Trials Succeed at ESMO, Overseas Commercialization Prospects Look Promising
    Huatai Securities · 2026/10/27
  • Company notice
    HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended October 31, 2026
    HKEX · 2026/11/2
  • Hutchmed (0013.HK): Two sets of Phase III data validate the potential of savolitinib in lung cancer treatment, paving the way for its global blockbuster trajectory.
    BOC International · 2026/11/10
  • Company notice
    HUTCHMED: VOLUNTARY ANNOUNCEMENT - Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
    HKEX · 2026/10/27
  • Rating change
    BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Raises Target Price to $18
    Market Newswire · 2026/9/21
  • Hong Kong Stock Market Update | Hutchmed (00013) rises over 4% as surufatinib receives FDA orphan drug designation for the treatment of autoimmune hemolytic anemia
    Zhitong Finance · 2026/11/5
  • Rating change
    HUTCHMED (00013.HK): Savolitinib U.S. Marketing Application; ESMO Announces SAFFRON Results
    CICC · 2026/10/27
  • Rating change
    Hutchmed (0013.HK): Savolitinib Shines in Two Phase III Studies at the 2026 ESMO Congress
    Citic Securities · 2026/10/30
  • Company notice
    HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
    HKEX · 2026/10/29
  • Rating change
    Hutchmed (00013.HK) Update: Dual Late-Breaking Abstracts Shine at ESMO as Savolitinib Accelerates Expansion
    Oriental Securities · 2026/10/30
  • Hutchmed (00013.HK): Sovleplenib Receives FDA Orphan Drug Designation for the Treatment of Autoimmune Hemolytic Anemia
    Gelonghui Finance · 2026/11/5
  • Company notice
    HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS plus TAGRISSO in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
    HKEX · 2026/11/2
  • Company notice
    HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
    HKEX · 2026/11/5
  • Rating change
    CICC: Maintains target price of HK$28 for Hutchmed (00013); rating remains "Outperform"
    Zhitong Finance · 2026/10/28
  • Rating change
    BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2026/10/27
  • Rating change
    Hutchmed (00013.HK): Clear survival benefit demonstrated with savolitinib combination regimen; precision medicine strategy shifts toward first-line treatment
    Soochow Securities · 2026/10/28
  • Rating change
    Hutchmed (00013.HK): Savolitinib Phase III trials globally validate the value of precision therapy targeting EGFR/cMET
    Open Source Securities · 2026/10/28
  • [Major Banks] Citi Raises Hutchmed's (00013.HK) Target Price to HK$43.2, Upgrades Revenue and EPS Forecasts, Names It New Top Pick
    AASTOCKS · 2026/11/6
  • Rating change
    Hutchmed (00013.HK): The SAFFRON global Phase III study of savolitinib has yielded positive results, potentially accelerating its global regulatory submissions.
    Dongwu Securities · 2026/8/18
  • HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
    GlobeNewswire · 2026/10/29
  • Rating change
    Hutchmed (0013.HK): ATTC licensing to GSK clarifies overseas expansion path
    Huatai Securities · 2026/9/3
  • Company notice
    HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
    HKEX · 2026/10/26
  • Rating change
    CICC: Maintains "Outperform" rating for Hutchmed (00013), raises target price to HK$28
    Zhitong Finance · 2026/9/8

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 16:10:04 · For reference only, not investment advice and not tailored to your situation.

Hutchmed (China) discussion 0 comments

Add a comment